Allogene Therapeutics, Inc. Common Stock ALLO
i
Market dataready · fetched 2026-11-11T14:52:03.429Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:52:00.646102387Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T14:52:02.973524+00:00
Allogene Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.40 | 234.8% | 57.6% | |||
| 25Δ | 1.29 | 210.8% | 46.2% | |||
| 30Δ | 1.18 | 186.7% | 34.8% | |||
| 35Δ | 1.07 | 162.7% | 23.4% | |||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | ||||||
| 60Δ | ||||||
| 65Δ | ||||||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- 1.40
- IV
- 234.8%
- B/E move
- 57.6%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 1.29
- IV
- 210.8%
- B/E move
- 46.2%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 1.18
- IV
- 186.7%
- B/E move
- 34.8%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 1.07
- IV
- 162.7%
- B/E move
- 23.4%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 94.97% | |
| 105.18% | |
| 125.49% | |
| 103.75% | |
| 109.79% | |
| 93.88% | |
| 97.88% | |
| 105.71% | |
| 91.95% | |
| 103.76% | |
| 73.74% | |
| 74.68% | |
| 82.53% | |
| 124.23% | |
| 119.42% | |
| 113.60% | |
| 110.07% | |
| 173.08% | |
| 140.72% | |
| 137.87% | |
| 119.21% |
Biotechnology
ALMS
Alumis Inc. (ALMS) is a prominent player in the aluminum sector, specializing in the development and commercialization of high-performance aluminum solutions for automotive,…
More →ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered…
More →ALT
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The…
More →ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame,…
More →ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company…
More →ANIX
Description unavailable
More →